(DCTH) will rise more than 200% on of before June 1st!
You can make more than a 200% gain on (DCTH)
Delcath's chemosaturation system as it presented a clear advantage over the control arm in phase 3 clinical trials -- more than tripling patient survival to 214 days, from 70 days.
Market valuation on this therapy is estimated at 500 million annually! Current market cap of (DCTH) is 120 million and the stock trades around $2.00! So if approved then market cap grows from 120, to 620 million, or $8.00 a share!
On or before June 15th 2013 this company will be FDA approved!
That is just less than 129 days away at the latest! It could come a few weeks early!
The time to buy shares is now!
Delcath Systems, Inc. (DCTH) -NasdaqCM
1.59 0.06(3.64%) 9:52AM EST - Nasdaq Real Time Price